<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02395471</url>
  </required_header>
  <id_info>
    <org_study_id>B-271</org_study_id>
    <nct_id>NCT02395471</nct_id>
  </id_info>
  <brief_title>Cytosponge Adequacy Study Evaluation II</brief_title>
  <acronym>CASEII</acronym>
  <official_title>Assessment of a Minimally Invasive Esophageal Cytology Collection System in Patients With Barrett's Esophagus or GERD Symptoms</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic - MITG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic - MITG</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will assess the Minimally Invasive Esophageal Cytology Collection System in
      Patients with Barrett's Esophagus or GERD Symptoms.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a cross-sectional study of subjects with Barrett's esophagus (BE) to assess the
      utility of the Cytosponge device as a non-endoscopic method for collecting surface cells from
      the esophagus. This study will enroll 2 groups of subjects: 1) Subjects presenting for
      routine endoscopic BE surveillance examinations (n=120), and 2) Subjects with
      gastroesophageal reflux disease (GERD) symptoms undergoing upper endoscopy for screening for
      BE (n=55). After informed consent, and on the same day as the endoscopic procedure, the
      subject will undergo administration of the Cytosponge device and complete a questionnaire.
      The subject will then undergo routine upper endoscopy, with assessment of BE (where
      applicable), and biopsy per accepted surveillance or screening recommendations. The
      Cytosponge will be placed in fixative and shipped to an accredited pathology laboratory for
      embedding in paraffin and hematoxylin and eosin (H&amp;E) staining to assess the adequacy of the
      specimen. Further evaluation of the specimen may be performed using trefoil factor 3 (TFF3).
      If the Cytosponge tissue specimen is inadequate, the subject will be recalled for a repeat
      sponge procedure (not endoscopy) 30 days later. Routine care tissue biopsies will undergo
      standard processing and H&amp;E staining at the home institution, with assessment by expert
      gastrointestinal pathologists. Subjects will be contacted via phone 7 days (+/- 2 days) after
      Cytosponge administration to complete additional questionnaires and assess adverse events.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Actual">June 1, 2018</completion_date>
  <primary_completion_date type="Actual">April 24, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedure Preference and Acceptability Questionnaire and Visual Analog Scale</measure>
    <time_frame>Immediately post procedure up to 7 days +/- 3 days</time_frame>
    <description>The first primary objective of the study was to assess the acceptability of a novel, minimally invasive esophageal mucosal sampling technique, the Cytosponge™, in subjects undergoing surveillance of BE who have had at least a C1 or M3 segment confirmed, and 2) in subjects with GERD undergoing screening for BE. This includes measures of acceptability as demonstrated on the Impact of Event Scale, a Visual Analog Scale for Pain, and the subject's willingness to undergo repeat Cytosponge™ administration if it were offered to him/her. The Visual Analog Scale is measured from 0-100 scale for pain, 0 representing no pain and 100 representing the highest level of pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Adequate Cytosponge™ Sample</measure>
    <time_frame>Immediately post procedure up to 7 days +/- 3 days</time_frame>
    <description>To assess the adequacy of cytology samples obtained by Cytosponge in this population after 1 sampling, and after 2 samplings if first sample inadequate.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Operating Characteristics</measure>
    <time_frame>Immediately post procedure up to 7 days +/- 3 days</time_frame>
    <description>The operating characteristics of this technique against a gold standard of upper endoscopy with biopsies for endoscopic surveillance in subjects with BE who demonstrate an adequate sample on Cytosponge assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytosponge™ Operating Characteristics vs Worst Histology Ever</measure>
    <time_frame>Immediately post procedure up to 7 days +/- 3 days</time_frame>
    <description>The second secondary objective was to assess the operating characteristics of Cytosponge™ against the worst ever histology documented in the subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cytosponge™ Operating Characteristics as a Function of Baseline Histology</measure>
    <time_frame>Immediately post procedure up to 7 days +/- 3 days</time_frame>
    <description>The third secondary objective was to assess the operating characteristics of Cytosponge™ as a function of baseline histology. At the outset of this study, no data was available regarding the accuracy of TFF3 in samples collected by Cytosponge™ in subjects with BE and more advanced disease (low-grade dysplasia and high-grade dysplasia). These subjects are at greatest risk for progression to cancer. We planned to collect pilot data on operating characteristics of the assay by degree of baseline dysplasia. We hypothesized that TFF3 would perform with similar operating characteristics in this group compared to non-dysplastic BE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Summary of Abrasion, Bleeding, and Perforation Observed Via Endoscopy</measure>
    <time_frame>Immediately post procedure up to 7 days +/- 3 days</time_frame>
    <description>The fourth secondary objective was to assess the degree of mucosal abrasion following Cytosponge™ administration, using a standardized scale. The incidence is presented in the data below for abrasion, bleeding and perforation observed during Endoscopy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ongoing Safety Measures</measure>
    <time_frame>Immediately post procedure up to 7 days +/- 3 days</time_frame>
    <description>To collect and analyze ongoing safety measures of Cytosponge use in the target population.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">191</enrollment>
  <condition>Barrett's Esophagus</condition>
  <condition>GERD</condition>
  <arm_group>
    <arm_group_label>Patient wth Barrett's</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects presenting for routine endoscopic BE surveillance examinations</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patients with GERD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects with gastroesophageal reflux disease (GERD) symptoms undergoing upper endoscopy for screening for BE</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Cytosponge™ Cell Collection Device</intervention_name>
    <description>Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.</description>
    <arm_group_label>Patient wth Barrett's</arm_group_label>
    <arm_group_label>Patients with GERD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Male or female subjects, age 18 and above.

          2. Able to read, comprehend, and complete the consent form.

          3. Clinically fit for an endoscopy.

          4. a) Previous confirmed diagnosis of Barrett's esophagus with intestinal metaplasia, and
             Prague classification of at least one circumferential centimeter of BE or a total BE
             segment length of at least 3 centimeters (C1+ or CXM3+) (BE arm) . OR b) If the
             subject does not have documented Prague Classification prior to screening, but the PI
             is convinced that the subject will meet the inclusion criteria based on previous
             documentation (for instance, mention of &quot;long-segment BE,&quot; they may enroll the subject
             in the study at their discretion. The study upper endoscopy must confirm that the
             subject has C1+ or CXM3+ (BE arm). If (C1+ or CXM3+) is not observed at the time of
             study endoscopy, the subject may still be enrolled but not included in the data
             analysis with the BE cohort. The data may be analyzed in a separate cohort. OR c)
             Self-reported heartburn or regurgitation on at least a monthly basis for at least 6
             months (GERD arm).

        Exclusion Criteria:

          1. Individuals with a diagnosis of an oropharynx, esophageal or gastro-esophageal tumor,
             or symptoms of dysphagia.

          2. Any history of esophageal varices, stricture, or prior dilation of the esophagus.

          3. Current use of anti-thrombotics (anti-coagulants and anti-platelet drugs) that cannot
             be safely discontinued for the appropriate drug-specific interval in the
             peri-administration period. Depending on the particular agent or reason for the
             anti-thrombotic therapy, it may not be necessary to discontinue anti-thrombotic
             agents. There could be circumstances where the drug may not need to be discontinued if
             the risk of bleeding is considered negligible (e.g. daily aspirin therapy). Physicians
             should use their clinical judgement and should consult guidelines such as those
             provided by the ASGE.

          4. Known bleeding disorder.

          5. Individuals who have had a myocardial infarction or any cardiac event &lt; 6 months prior
             to enrollment.

          6. Individuals who have had a cerebrovascular event &lt; 6 months prior to enrollment in
             which swallowing was affected.

          7. Prior ablative or resection therapy of the esophagus including radiofrequency ablation
             (RFA), photodynamic therapy (PDT), spray cryotherapy, endoscopic mucosal resection,
             and other ablation therapies.

          8. Any history of esophageal surgery, except for uncomplicated fundoplication.

          9. Do not need upper endoscopy as part of patient management.

         10. Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Amanda Cafaro, BSN</last_name>
    <role>Study Director</role>
    <affiliation>Medtronic Clinical Research Director</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Univeristy of California, Los Angeles</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwestern University</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of North Carolina</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599-7080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gastrointestinal Associates</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37909</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>March 12, 2015</study_first_submitted>
  <study_first_submitted_qc>March 17, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2015</study_first_posted>
  <results_first_submitted>April 24, 2019</results_first_submitted>
  <results_first_submitted_qc>July 9, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">July 30, 2019</results_first_posted>
  <last_update_submitted>July 9, 2019</last_update_submitted>
  <last_update_submitted_qc>July 9, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barrett Esophagus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>December 1, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02395471/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 20, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/71/NCT02395471/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Patient Wth Barrett's</title>
          <description>Subjects presenting for routine endoscopic BE surveillance examinations
Cytosponge™ Cell Collection Device: Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.</description>
        </group>
        <group group_id="P2">
          <title>Patients With GERD</title>
          <description>Subjects with gastroesophageal reflux disease (GERD) symptoms undergoing upper endoscopy for screening for BE
Cytosponge™ Cell Collection Device: Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="129"/>
                <participants group_id="P2" count="62"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="122"/>
                <participants group_id="P2" count="59"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Failure to swollow sponge twice</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient did not return for procedure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject not eligible</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Patient Wth Barrett's</title>
          <description>Subjects presenting for routine endoscopic BE surveillance examinations
Cytosponge™ Cell Collection Device: Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.</description>
        </group>
        <group group_id="B2">
          <title>Patients With GERD</title>
          <description>Subjects with gastroesophageal reflux disease (GERD) symptoms undergoing upper endoscopy for screening for BE
Cytosponge™ Cell Collection Device: Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="129"/>
            <count group_id="B2" value="62"/>
            <count group_id="B3" value="191"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64" spread="10.4"/>
                    <measurement group_id="B2" value="54.2" spread="15.1"/>
                    <measurement group_id="B3" value="60.8" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="36"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="75"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="93"/>
                    <measurement group_id="B2" value="23"/>
                    <measurement group_id="B3" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="57"/>
                    <measurement group_id="B3" value="184"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>In Patients with GERD, one patient was both American Indian Or Alaska Native and Asian.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>American Indian Or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black or African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or Other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="127"/>
                    <measurement group_id="B2" value="52"/>
                    <measurement group_id="B3" value="179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Procedure Preference and Acceptability Questionnaire and Visual Analog Scale</title>
        <description>The first primary objective of the study was to assess the acceptability of a novel, minimally invasive esophageal mucosal sampling technique, the Cytosponge™, in subjects undergoing surveillance of BE who have had at least a C1 or M3 segment confirmed, and 2) in subjects with GERD undergoing screening for BE. This includes measures of acceptability as demonstrated on the Impact of Event Scale, a Visual Analog Scale for Pain, and the subject's willingness to undergo repeat Cytosponge™ administration if it were offered to him/her. The Visual Analog Scale is measured from 0-100 scale for pain, 0 representing no pain and 100 representing the highest level of pain.</description>
        <time_frame>Immediately post procedure up to 7 days +/- 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Study Participant Cytosponge Procedure Acceptability</title>
            <description>Acceptability of the Cytosponge Procedure by all study subjects that underwent both Cytosponge and Endoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Procedure Preference and Acceptability Questionnaire and Visual Analog Scale</title>
          <description>The first primary objective of the study was to assess the acceptability of a novel, minimally invasive esophageal mucosal sampling technique, the Cytosponge™, in subjects undergoing surveillance of BE who have had at least a C1 or M3 segment confirmed, and 2) in subjects with GERD undergoing screening for BE. This includes measures of acceptability as demonstrated on the Impact of Event Scale, a Visual Analog Scale for Pain, and the subject's willingness to undergo repeat Cytosponge™ administration if it were offered to him/her. The Visual Analog Scale is measured from 0-100 scale for pain, 0 representing no pain and 100 representing the highest level of pain.</description>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>On scale of 0-10 (10-high), rate Cytosponge exper.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.2" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>On scale of 0-10 (10-high), rate endoscopy exper.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.5" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Diff. between the two scales: (Cyto/Endoscop)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Visual Analog Scale</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="18.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Adequate Cytosponge™ Sample</title>
        <description>To assess the adequacy of cytology samples obtained by Cytosponge in this population after 1 sampling, and after 2 samplings if first sample inadequate.</description>
        <time_frame>Immediately post procedure up to 7 days +/- 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Patient Wth Barrett's</title>
            <description>Subjects presenting for routine endoscopic BE surveillance examinations
Cytosponge™ Cell Collection Device: Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.</description>
          </group>
          <group group_id="O2">
            <title>Patients With GERD</title>
            <description>Subjects with gastroesophageal reflux disease (GERD) symptoms undergoing upper endoscopy for screening for BE
Cytosponge™ Cell Collection Device: Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adequate Cytosponge™ Sample</title>
          <description>To assess the adequacy of cytology samples obtained by Cytosponge in this population after 1 sampling, and after 2 samplings if first sample inadequate.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="127"/>
                <count group_id="O2" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Operating Characteristics</title>
        <description>The operating characteristics of this technique against a gold standard of upper endoscopy with biopsies for endoscopic surveillance in subjects with BE who demonstrate an adequate sample on Cytosponge assessment.</description>
        <time_frame>Immediately post procedure up to 7 days +/- 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Operating Characteristics of Cytosponge™/TFF3 vs BE Diagnosis</title>
            <description>Sensitivity, Specificity, PPV, NPV, and Accuracy of Cytosponge™/TFF3 vs. the Gold Standard of Endoscopy for BE Diagnosis</description>
          </group>
        </group_list>
        <measure>
          <title>Operating Characteristics</title>
          <description>The operating characteristics of this technique against a gold standard of upper endoscopy with biopsies for endoscopic surveillance in subjects with BE who demonstrate an adequate sample on Cytosponge assessment.</description>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="154"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.5" lower_limit="65.6" upper_limit="83.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.7" lower_limit="64" upper_limit="86.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive Predictive Value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83.5" lower_limit="73.9" upper_limit="90.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Accuracy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76" lower_limit="68.4" upper_limit="82.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cytosponge™ Operating Characteristics vs Worst Histology Ever</title>
        <description>The second secondary objective was to assess the operating characteristics of Cytosponge™ against the worst ever histology documented in the subject.</description>
        <time_frame>Immediately post procedure up to 7 days +/- 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Cytosponge™ Operating Characteristics vs Worst Histology</title>
            <description>The second secondary objective was to assess the operating characteristics of Cytosponge™ against the worst ever histology documented in the subject.</description>
          </group>
        </group_list>
        <measure>
          <title>Cytosponge™ Operating Characteristics vs Worst Histology Ever</title>
          <description>The second secondary objective was to assess the operating characteristics of Cytosponge™ against the worst ever histology documented in the subject.</description>
          <units>Percentage</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="158"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="77" lower_limit="67.5" upper_limit="84.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81" lower_limit="68.6" upper_limit="90.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Positive Predictive Value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87.5" lower_limit="78.7" upper_limit="93.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Negative Predictive Value</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67.1" lower_limit="54.9" upper_limit="77.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Accuracy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="78.5" lower_limit="71.2" upper_limit="84.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cytosponge™ Operating Characteristics as a Function of Baseline Histology</title>
        <description>The third secondary objective was to assess the operating characteristics of Cytosponge™ as a function of baseline histology. At the outset of this study, no data was available regarding the accuracy of TFF3 in samples collected by Cytosponge™ in subjects with BE and more advanced disease (low-grade dysplasia and high-grade dysplasia). These subjects are at greatest risk for progression to cancer. We planned to collect pilot data on operating characteristics of the assay by degree of baseline dysplasia. We hypothesized that TFF3 would perform with similar operating characteristics in this group compared to non-dysplastic BE.</description>
        <time_frame>Immediately post procedure up to 7 days +/- 3 days</time_frame>
        <population>Among study subjects with BE that exhibited HGD, there were no true negatives or false positives, therefore specificity of the assay was not calculated for this subgroup.</population>
        <group_list>
          <group group_id="O1">
            <title>Non-Dysplastic BE</title>
            <description>Non-Dysplastic BE</description>
          </group>
          <group group_id="O2">
            <title>Indefinite for Dysplasia</title>
            <description>Indefinite for Dysplasia</description>
          </group>
          <group group_id="O3">
            <title>Low Grade Dysplasia</title>
            <description>Low Grade Dysplasia</description>
          </group>
          <group group_id="O4">
            <title>High Grade Dysplasia</title>
            <description>High Grade Dysplasia</description>
          </group>
        </group_list>
        <measure>
          <title>Cytosponge™ Operating Characteristics as a Function of Baseline Histology</title>
          <description>The third secondary objective was to assess the operating characteristics of Cytosponge™ as a function of baseline histology. At the outset of this study, no data was available regarding the accuracy of TFF3 in samples collected by Cytosponge™ in subjects with BE and more advanced disease (low-grade dysplasia and high-grade dysplasia). These subjects are at greatest risk for progression to cancer. We planned to collect pilot data on operating characteristics of the assay by degree of baseline dysplasia. We hypothesized that TFF3 would perform with similar operating characteristics in this group compared to non-dysplastic BE.</description>
          <population>Among study subjects with BE that exhibited HGD, there were no true negatives or false positives, therefore specificity of the assay was not calculated for this subgroup.</population>
          <units>Percentage</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="77"/>
                <count group_id="O2" value="13"/>
                <count group_id="O3" value="10"/>
                <count group_id="O4" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.2"/>
                    <measurement group_id="O2" value="66.7"/>
                    <measurement group_id="O3" value="77.8"/>
                    <measurement group_id="O4" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Specificity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64.3"/>
                    <measurement group_id="O2" value="100"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="NA">Analysis not available, See Population Description.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Accuracy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.0"/>
                    <measurement group_id="O2" value="69.2"/>
                    <measurement group_id="O3" value="70.0"/>
                    <measurement group_id="O4" value="83.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Summary of Abrasion, Bleeding, and Perforation Observed Via Endoscopy</title>
        <description>The fourth secondary objective was to assess the degree of mucosal abrasion following Cytosponge™ administration, using a standardized scale. The incidence is presented in the data below for abrasion, bleeding and perforation observed during Endoscopy.</description>
        <time_frame>Immediately post procedure up to 7 days +/- 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Incidence</title>
            <description>Incidence of Abrasion, Bleeding and Perforation observed via Endoscopy</description>
          </group>
        </group_list>
        <measure>
          <title>Summary of Abrasion, Bleeding, and Perforation Observed Via Endoscopy</title>
          <description>The fourth secondary objective was to assess the degree of mucosal abrasion following Cytosponge™ administration, using a standardized scale. The incidence is presented in the data below for abrasion, bleeding and perforation observed during Endoscopy.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="190"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Abrasion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="117"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding-From Cytosponge contact site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bleeding-From Biopsy Site</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Perforation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any of These 3 Conditions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="141"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Ongoing Safety Measures</title>
        <description>To collect and analyze ongoing safety measures of Cytosponge use in the target population.</description>
        <time_frame>Immediately post procedure up to 7 days +/- 3 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Incidence of AE's</title>
            <description>Incidence of AE's</description>
          </group>
        </group_list>
        <measure>
          <title>Ongoing Safety Measures</title>
          <description>To collect and analyze ongoing safety measures of Cytosponge use in the target population.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Not Coded</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dyspepsia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vomiting</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest Discomfort</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Device Breakage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oropharyngeal Pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Throat Irritation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Subjects will be contacted 7 days (+/- 2 days) following the Cytosponge and upper endoscopy procedures. During this phone call, adverse events will be assessed and subjects will complete questionnaires. Participation in the study is complete when subjects have completed the follow-up phone call.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Patient Wth Barrett's</title>
          <description>Subjects presenting for routine endoscopic BE surveillance examinations who had at least a C1 or M3 segment confirmed (or medically suspected).
Cytosponge™ Cell Collection Device: Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.</description>
        </group>
        <group group_id="E2">
          <title>Patients With GERD</title>
          <description>Subjects with gastroesophageal reflux disease (GERD) symptoms undergoing screening for BE
Cytosponge™ Cell Collection Device: Cytosponge™ Cell Collection Device is indicated for use in the collection and retrieval of surface cells in the esophagus.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Sponge Detachment</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="129"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Not Coded</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device Breakage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="129"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="62"/>
              </event>
              <event>
                <sub_title>Throat Irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="129"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="62"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr.Jaime Kean</name_or_title>
      <organization>Medtronic MITG Gastrointestinal &amp; Hepatology</organization>
      <phone>303-882-6759</phone>
      <email>Jaime.M.Kean@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

